Startseite Kongressberichte & Archiv ESMO VIRTUAL 2020 Breast cancer Proffered Paper - Breast cancer, metastatic 2

Proffered Paper - Breast cancer, metastatic 2

LINK to Proffered Paper - Breast cancer, metastatic 2

LINK to STREAM (needs an ESMO registration)

274O - Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study

The abstract concludes: Overall, addition of veliparib to paclitaxel/carboplatin has no detrimental effect on quality of life in pts with gBRCA mutation-associated advanced breast cancer and may be beneficial in some areas of functioning and symptom experience.

 

275O - Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)

The abstract concludes: In H2C, addition of TUC resulted in statistically significant and clinically meaningful improvement in PFS and OS. Moreover, QoL in pts treated with TUC + T + C was maintained throughout the tx period which was longer compared to pts receiving only T + C.

 

276O - Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC)

The abstract concludes: In pts receiving first-line ET across the ML trials, RIB delayed deterioration in QOL. TTDD for GHS, pain, and emotional functioning scores was longer with RIB vs. PBO. Overall, this large, robust analysis demonstrated favorable QOL results with the addition of RIB to ET in patients with HR+/HER2− ABC.

 

LBA19 - GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)

The abstract concludes: P/F significantly improved 1-year PFS rate compared to F/PL in pts with HR+/HER2- endocrine sensitive ABC. P/F also improved median PFS and ORR. These data provide evidence for superiority of F/P vs. F/PL in an ABC population not represented in the pivotal PALOMA3 trial.